Prediction of Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SPS 2018]

Presented at the Safety Pharmacology Annual Meeting in Washington, DC; September/October 2018

Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% if safety-related withdrawals of FDA-approved drugs from the market. Current cardiac safety preclinical evaluations are heavily focused on electrophysiological assessment and fail to evaluate cardiomyopathy and other forms of structural cardiotoxicity. A new biomarker-based assay, which evaluates the cardiotoxicity potential of compounds based on changes in the metabolism, classified 78 compounds with known cardiotoxicity outcomes with 86% accuracy, 92% sensitivity, and 79% specificity.